cilengitide has been researched along with Benign Neoplasms in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patterson, LH; Sheldrake, HM | 1 |
| Eadens, M; Erlichman, C; Goetz, MP; Haddad, T; Lupu, R; Molina, J; Qin, R; Satele, D | 1 |
| Bazzazi, H; Jafarnejad, M; Popel, AS; Zhang, Y | 1 |
| Bhattaram, VA; Campioni, M; Derendorf, H; Kovar, A; Krösser, S; Zühlsdorf, M | 1 |
| Cohen, EE; Fleming, GF; Harris, PJ; Janisch, L; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; O'Donnell, PH; Polite, BN; Ratain, MJ | 1 |
| Bergers, G; Rivera, LB | 1 |
| Colombo, L; Paolillo, M; Russo, MA; Schinelli, S; Serra, M | 1 |
| Carter, A | 1 |
| Janisch, L; Karrison, TM; Nicholas, MK; O'Donnell, PH; Ratain, MJ; Stadler, WM; Undevia, SD | 1 |
| Imaizumi, N; Kuonen, F; Monnier, Y; Rüegg, C | 1 |
| Böttcher, S; Brindley, C; Drevs, J; Dumez, H; Eskens, FA; Hoekstra, R; Perschl, A; van Oosterom, AT; Verweij, J; Wynendaele, W | 1 |
| Smith, JW | 1 |
| Colevas, AD; Scharf, O; Schoenfeldt, M | 1 |
| Achilefu, S; Bloch, S; Chance, B; Dorshow, RB; Liang, K; Markiewicz, MA; Ye, Y; Zhong, T | 1 |
| Tucker, GC | 1 |
| Cai, W; Chen, X | 1 |
| Ruegg, C; Stupp, R | 1 |
| Kibble, A; Shumoogam, J; Walker, K | 1 |
| Baron, A; Basche, M; Colevas, D; Davis, D; Eckhardt, SG; Gallemann, D; Gore, L; Gustafson, D; Hariharan, S; Holden, S; McConkey, D; Morrow, M; O'Bryant, CL; Zang, C | 1 |
| Finn, R | 1 |
5 review(s) available for cilengitide and Benign Neoplasms
| Article | Year |
|---|---|
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Binding Sites; Humans; Integrins; Molecular Targeted Therapy; Neoplasms; Oligopeptides; Protein Conformation | 2014 |
Small molecule integrin antagonists in cancer therapy.
Topics: Anoikis; Humans; Indoles; Integrin alphaVbeta3; Integrins; Neoplasms; Peptides; Receptors, Vitronectin; Signal Transduction; Snake Venoms; Sulfonamides | 2009 |
Cilengitide Merck.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drugs, Investigational; Humans; Neoplasms; Snake Venoms; Technology, Pharmaceutical | 2003 |
Integrins: molecular targets in cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Indoles; Integrins; Melanoma; Neoplasms; Porphyrins; Skin Neoplasms; Snake Venoms; Sulfonamides | 2006 |
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disintegrins; Drug Delivery Systems; Gene Silencing; Gene Targeting; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Neoplasms; Oligopeptides; Positron-Emission Tomography; RNA, Small Interfering; Snake Venoms; Tomography, Emission-Computed, Single-Photon; Ultrasonography | 2006 |
6 trial(s) available for cilengitide and Benign Neoplasms
| Article | Year |
|---|---|
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Integrin alphaVbeta3; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Vitronectin; Snake Venoms; Treatment Outcome | 2017 |
Population pharmacokinetics of cilengitide in adult and pediatric cancer patients from a nonlinear mixed-effects analysis.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Body Surface Area; Body Weight; Child; Computer Simulation; Humans; Middle Aged; Models, Biological; Neoplasms; Snake Venoms | 2014 |
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Collagen Type I; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Peptides; Pyrroles; Snake Venoms; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
A phase I study of continuous infusion cilengitide in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Chicago; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Snake Venoms; Treatment Outcome | 2012 |
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Integrin alphaVbeta3; Integrins; Male; Middle Aged; Neoplasms; Receptors, Vitronectin; Snake Venoms | 2003 |
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression; Humans; In Situ Nick-End Labeling; Integrin alphaVbeta3; Integrins; Neoplasms; Receptors, Vitronectin; Snake Venoms | 2007 |
9 other study(ies) available for cilengitide and Benign Neoplasms
| Article | Year |
|---|---|
Computational modeling of synergistic interaction between αVβ3 integrin and VEGFR2 in endothelial cells: Implications for the mechanism of action of angiogenesis-modulating integrin-binding peptides.
Topics: Autoantigens; Collagen Type IV; Endothelial Cells; Humans; Integrin alphaVbeta3; Models, Biological; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Signal Transduction; Snake Venoms; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
CANCER. Tumor angiogenesis, from foe to friend.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Humans; Neoplasm Recurrence, Local; Neoplasms; Neovascularization, Pathologic; Snake Venoms | 2015 |
Integrins as target: first phase III trial launches, but questions remain.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Glioblastoma; Humans; Integrins; Neoplasms; Snake Venoms | 2010 |
Radiation-induced modifications of the tumor microenvironment promote metastasis.
Topics: Angiogenesis Inhibitors; Cell Hypoxia; Cell Movement; Cell Proliferation; Cysteine-Rich Protein 61; Disease Progression; Endothelial Cells; Humans; Microvessels; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Receptors, Vitronectin; Snake Venoms; Tumor Microenvironment | 2011 |
Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Integrin alphaV; Neoplasms; Snake Venoms | 2004 |
Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression.
Topics: Animals; Carbocyanines; Fluorometry; Integrins; Ligands; Mice; Mice, Nude; Microscopy, Fluorescence; Molecular Probe Techniques; Neoplasms; Oligopeptides; Peptides, Cyclic; Snake Venoms; Spectrophotometry; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2005 |
Integrin inhibitors reaching the clinic.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Growth Substances; Humans; Integrins; Neoplasms; Snake Venoms; Treatment Outcome | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Biomedical Research; CA-125 Antigen; Clinical Trials as Topic; Dasatinib; Female; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Ovarian Neoplasms; Pyrimidines; Snake Venoms; Sulfonamides; Thiazoles; Treatment Outcome | 2007 |
Snake venom protein paralyzes cancer cells.
Topics: Agkistrodon; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Adhesion; Cell Movement; Disintegrins; Drugs, Investigational; Humans; Neoplasms; Snake Venoms | 2001 |